Literature DB >> 19602568

Immunological mimicry of PrPC-PrPSc interactions: antibody-induced PrP misfolding.

Li Li1, Will Guest, Alan Huang, Steven S Plotkin, Neil R Cashman.   

Abstract

Prion diseases are associated with the conversion of cellular prion protein (PrP(C)) to an abnormal protease-resistant conformational isoform (PrP(Sc)) by template-directed conversion. The interaction between PrP(C) and PrP(Sc) is mediated by specific sites which have been mapped to six putative 'binding and conversion domains' (PrP-BCD) through peptide and antibody competition studies. Monoclonal antibodies (mAbs) directed against the bityrosine motif Tyr-Tyr-Arg (YYR) specifically recognize PrP(Sc) and other misfolded PrP species. Here, we report that select bead-bound PrP-BCD mAbs induce exposure of bityrosine epitopes on mouse brain PrP. By competition immunoprecipitation, we show that PrP-BCD mAb-induced bityrosine exposure occurs at alpha-helices 1 and 3. However, PrP-BCD mAb-induced PrP(C) misfolding is not accompanied by beta-sheet dissociation, a key event in PrP(C) conversion to PrP(Sc), and is not associated with acquisition of protease resistance, or the capacity to recruit additional molecules of PrP. Our data suggest that mAb mimics of the physical interaction of PrP(C) with PrP(Sc) can induce unfolding of specific PrP domains, but that subsequent processes (including the energetically unfavorable beta-sheet dissociation) effect isoform conversion in prion disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602568     DOI: 10.1093/protein/gzp038

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  8 in total

1.  PrP(Sc)-specific antibodies do not induce prion disease or misfolding of PrP(C) in highly susceptible Tga20 mice.

Authors:  Pekka Määttänen; Ryan Taschuk; Li Ross; Kristen Marciniuk; Lisa Bertram; Andrew Potter; Neil R Cashman; Scott Napper
Journal:  Prion       Date:  2013-10-08       Impact factor: 3.931

2.  SOD1 exhibits allosteric frustration to facilitate metal binding affinity.

Authors:  Atanu Das; Steven S Plotkin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

3.  Zinc drives a tertiary fold in the prion protein with familial disease mutation sites at the interface.

Authors:  Ann R Spevacek; Eric G B Evans; Jillian L Miller; Heidi C Meyer; Jeffrey G Pelton; Glenn L Millhauser
Journal:  Structure       Date:  2013-01-03       Impact factor: 5.006

Review 4.  Implications of peptide assemblies in amyloid diseases.

Authors:  Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

Review 5.  PrP overdrive: does inhibition of α-cleavage contribute to PrP(C) toxicity and prion disease?

Authors:  Alex J McDonald; Glenn L Millhauser
Journal:  Prion       Date:  2014-04-10       Impact factor: 3.931

6.  The Effects of Ca2+ Concentration and E200K Mutation on the Aggregation Propensity of PrPC: A Computational Study.

Authors:  Alessandro Marrone; Nazzareno Re; Loriano Storchi
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

7.  Prion protein-specific antibodies that detect multiple TSE agents with high sensitivity.

Authors:  Sandra McCutcheon; Jan P M Langeveld; Boon Chin Tan; Andrew C Gill; Christopher de Wolf; Stuart Martin; Lorenzo Gonzalez; James Alibhai; A Richard Alejo Blanco; Lauren Campbell; Nora Hunter; E Fiona Houston
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

8.  Human serum antibodies against EBV latent membrane protein 1 cross-react with α-synuclein.

Authors:  John Woulfe; Madison T Gray; Munisha S Ganesh; Jaap M Middeldorp
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.